These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14505892)

  • 1. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV.
    Kallinteris NL; Lu X; Wu S; Hu H; Li Y; Gulfo JV; Humphreys RE; Xu M
    Vaccine; 2003 Oct; 21(27-30):4128-32. PubMed ID: 14505892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.
    Kallinteris NL; Lu X; Blackwell CE; von Hofe E; Humphreys RE; Xu M
    Expert Opin Biol Ther; 2006 Dec; 6(12):1311-21. PubMed ID: 17223739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
    Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
    Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
    Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
    Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
    Berzofsky JA
    Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.
    Bozzacco L; Yu H; Dengjel J; Trumpfheller C; Zebroski HA; Zhang N; Küttner V; Ueberheide BM; Deng H; Chait BT; Steinman RM; Mojsov S; Fenyö D
    PLoS One; 2012; 7(7):e41897. PubMed ID: 22860026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
    J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
    Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
    Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines.
    Moukrim Z; Cho YY; Mbika JP; Achour A
    Biomed Pharmacother; 1996; 50(10):494-9. PubMed ID: 9091063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice.
    Suh CH; Freed JH; Cohen PL
    J Immunol; 2003 Feb; 170(4):2229-35. PubMed ID: 12574397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.
    Kallinteris NL; Wu S; Lu X; von Hofe E; Humphreys RE; Xu M
    Vaccine; 2005 Mar; 23(17-18):2336-8. PubMed ID: 15755623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 epitope peptides induce protective immunity against Rickettsia rickettsii infection in C3H/HeN mice.
    Wang P; Xiong X; Jiao J; Yang X; Jiang Y; Wen B; Gong W
    Vaccine; 2017 Dec; 35(51):7204-7212. PubMed ID: 29032899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.
    Humphreys RE; Adams S; Koldzic G; Nedelescu B; von Hofe E; Xu M
    Vaccine; 2000 Jun; 18(24):2693-7. PubMed ID: 10781856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
    Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
    Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip.
    Gaseitsiwe S; Valentini D; Ahmed R; Mahdavifar S; Magalhaes I; Zerweck J; Schutkowski M; Gautherot E; Montero F; Ehrnst A; Reilly M; Maeurer M
    Clin Vaccine Immunol; 2009 Apr; 16(4):567-73. PubMed ID: 19225081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.